Notice that juvenile DCs don't have the same sensitivity to PDL-1 interference issues ie Direct. Also note that removed tumor processed and lysed will not have a continual active source and that DCs must pass the selection test for potency. When injected intradermally in the arms these DCs are far away from the tumor bed and tumor draining lymph nodes where PDL-1 activity is interfering at a high rate and enter into a lymphoid rich zone with greatly reduced interference. NWBO has worked around quite a few of the issues others are still working on. Kat's Cure without checkpoint inhibitors tells us that at least in some cases checkpoint inhibitors are not needed. Has NWBO found ways to work around the need for checkpoint inhibitors to a wider extent than letting on? Good question. Enquiring pharmas like Merck wanted to know. Best wishes.
News 
Market Data 
Discover 
